Literature DB >> 12773292

Familial severe myoclonic epilepsy of infancy: truncation of Nav1.1 and genetic heterogeneity.

Elena Gennaro1, Pierangelo Veggiotti, Michele Malacarne, Francesca Madia, Massimiliano Cecconi, Simonetta Cardinali, Alessandra Cassetti, Ilaria Cecconi, Enrico Bertini, Amedeo Bianchi, Giuseppe Gobbi, Federico Zara.   

Abstract

BACKGROUND: Severe myoclonic epilepsy of infancy (SMEI) or Dravet syndrome has been long suspected of having a genetic origin. Recently, mutations in SCN1A and GABRG2 have been described in SMEI patients. The sporadic nature of the SMEI syndrome and the occurrence of SCN1A and GABRG2 mutations in a mild familial phenotype, termed generalized epilepsy with febrile seizure plus complicates genotype-phenotype correlations. In order to further investigate the role of SCN1A and GABRG2 in the pathogenesis of SMEI we have screened for mutations three families with at least two members affected by Dravet syndrome.
METHODS: Clinical criteria followed the international classification of epileptic syndromes. Mutational screening of SCN1A and GABRG2 genes was performed by denaturing high performance liquid chromatography (DHPLC) and direct sequencing of DNA fragments showing a variant chromatogram.
RESULTS: Thirty-eight fragments spanning 26 exons of SCN1A and nine exons of GABRG2 were analysed in three probands. Five variant chromatograms were identified; four corresponded to known polymorphisms, one to a novel dinucleotide insertion on exon 26 of SCN1A. The mutation leads to a frameshift and a premature stop codon at amino acid 1 779 of the protein. The mutation was present in the affected sibling and was inherited from the mother who had experienced a single febrile seizure in childhood.
CONCLUSIONS: Among three families analysed, a single family was mutant for SCN1A. Our study suggests that the syndrome is genetically heterogeneous. The variable expressivity we observed for the c5240insAA mutation suggests that other factors are needed for the development of the full SMEI phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12773292

Source DB:  PubMed          Journal:  Epileptic Disord        ISSN: 1294-9361            Impact factor:   1.819


  12 in total

Review 1.  Sodium channel mutations in epilepsy and other neurological disorders.

Authors:  Miriam H Meisler; Jennifer A Kearney
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

2.  Nav 1.1 dysfunction in genetic epilepsy with febrile seizures-plus or Dravet syndrome.

Authors:  Linda Volkers; Kristopher M Kahlig; Nienke E Verbeek; Joost H G Das; Marjan J A van Kempen; Hans Stroink; Paul Augustijn; Onno van Nieuwenhuizen; Dick Lindhout; Alfred L George; Bobby P C Koeleman; Martin B Rook
Journal:  Eur J Neurosci       Date:  2011-08-22       Impact factor: 3.386

3.  NBI-921352, a first-in-class, NaV1.6 selective, sodium channel inhibitor that prevents seizures in Scn8a gain-of-function mice, and wild-type mice and rats.

Authors:  J P Johnson; Thilo Focken; Kuldip Khakh; Parisa Karimi Tari; Celine Dube; Samuel J Goodchild; Jean-Christophe Andrez; Girish Bankar; David Bogucki; Kristen Burford; Elaine Chang; Sultan Chowdhury; Richard Dean; Gina de Boer; Shannon Decker; Christoph Dehnhardt; Mandy Feng; Wei Gong; Michael Grimwood; Abid Hasan; Angela Hussainkhel; Qi Jia; Stephanie Lee; Jenny Li; Sophia Lin; Andrea Lindgren; Verner Lofstrand; Janette Mezeyova; Rostam Namdari; Karen Nelkenbrecher; Noah Gregory Shuart; Luis Sojo; Shaoyi Sun; Matthew Taron; Matthew Waldbrook; Diana Weeratunge; Steven Wesolowski; Aaron Williams; Michael Wilson; Zhiwei Xie; Rhena Yoo; Clint Young; Alla Zenova; Wei Zhang; Alison J Cutts; Robin P Sherrington; Simon N Pimstone; Raymond Winquist; Charles J Cohen; James R Empfield
Journal:  Elife       Date:  2022-03-02       Impact factor: 8.140

4.  "Epileptic encephalopathy" of infancy and childhood: electro-clinical pictures and recent understandings.

Authors:  Pasquale Parisi; Alberto Spalice; Francesco Nicita; Laura Papetti; Fabiana Ursitti; Alberto Verrotti; Paola Iannetti; Maria Pia Villa
Journal:  Curr Neuropharmacol       Date:  2010-12       Impact factor: 7.363

5.  A functional null mutation of SCN1B in a patient with Dravet syndrome.

Authors:  Gustavo A Patino; Lieve R F Claes; Luis F Lopez-Santiago; Emily A Slat; Raja S R Dondeti; Chunling Chen; Heather A O'Malley; Charles B B Gray; Haruko Miyazaki; Nobuyuki Nukina; Fumitaka Oyama; Peter De Jonghe; Lori L Isom
Journal:  J Neurosci       Date:  2009-08-26       Impact factor: 6.167

6.  Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation.

Authors:  Ikuo Ogiwara; Hiroyuki Miyamoto; Noriyuki Morita; Nafiseh Atapour; Emi Mazaki; Ikuyo Inoue; Tamaki Takeuchi; Shigeyoshi Itohara; Yuchio Yanagawa; Kunihiko Obata; Teiichi Furuichi; Takao K Hensch; Kazuhiro Yamakawa
Journal:  J Neurosci       Date:  2007-05-30       Impact factor: 6.167

7.  Epileptic encephalopathies in adults and childhood.

Authors:  Zekiye Kural; Ali Fahir Ozer
Journal:  Epilepsy Res Treat       Date:  2012-09-27

8.  A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome.

Authors:  Nanda A Singh; Chris Pappas; E Jill Dahle; Lieve R F Claes; Timothy H Pruess; Peter De Jonghe; Joel Thompson; Missy Dixon; Christina Gurnett; Andy Peiffer; H Steve White; Francis Filloux; Mark F Leppert
Journal:  PLoS Genet       Date:  2009-09-18       Impact factor: 5.917

9.  Identification of SCN1A and PCDH19 mutations in Chinese children with Dravet syndrome.

Authors:  Anna Ka-Yee Kwong; Cheuk-Wing Fung; Siu-Yuen Chan; Virginia Chun-Nei Wong
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

10.  Febrile temperatures unmask biophysical defects in Nav1.1 epilepsy mutations supportive of seizure initiation.

Authors:  Linda Volkers; Kristopher M Kahlig; Joost H G Das; Marjan J A van Kempen; Dick Lindhout; Bobby P C Koeleman; Martin B Rook
Journal:  J Gen Physiol       Date:  2013-12       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.